Phase 3 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People between 18 and 75 years old.
• People who are well enough to carry out basic daily activities (as measured by a standard medical scale called ECOG, scoring 0 to 2, meaning fully active to capable of light activity).
• People who have been diagnosed through a tissue biopsy with one of these specific types of T-cell lymphoma: ALK-negative Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-cell Lymphoma (AITL), Nodal PTCL with follicular helper T cell (TFH) features, or Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS).
• People who have already received a type of chemotherapy called anthracycline-based treatment as their initial (induction) treatment — even if the anthracycline was stopped early, as long as at least one dose was received and the cancer went into complete remission.
• People whose cancer has gone into complete remission (no signs of cancer remaining) after initial chemotherapy, confirmed by a PET-CT scan using a standard scoring system (Deauville score of 1 to 3).
• People whose bone marrow showed cancer at diagnosis must have had a repeat bone marrow biopsy after chemotherapy confirming the cancer is in remission.
• People who the treating centre considers medically suitable to receive high-dose chemotherapy and a stem cell transplant, and who are prepared to undergo that transplant if assigned to that treatment group.
• People with a history of another cancer, where that cancer or its treatment is unlikely to affect the safety or results of this trial.
• People living with HIV who are on effective HIV treatment with an undetectable level of virus in their blood within the 6 months before joining.
• People with a history of chronic Hepatitis B virus (HBV) who have an undetectable viral load while on appropriate treatment.
• People with a history of Hepatitis C virus (HCV) who have been successfully treated and cured, or who are currently on HCV treatment with an undetectable viral load.
• People whose recent blood test results (taken within 14 days before joining) meet minimum levels for white blood cells, platelets, and liver function (confirm specific values with trial site).

Who may not be able to join:

• People who have an active infection currently being treated with intravenous (IV) antibiotics or antimicrobials at the time of joining — though people taking a stable preventative (prophylactic) dose of antibiotics for at least 7 days may still be considered.
• People who are currently pregnant or breastfeeding, due to potential harm to an unborn baby or nursing infant from the treatments used in this trial.
• People who are capable of becoming pregnant and have not had a pregnancy test (blood or urine) within 14 days before joining.
• People who are not willing or able to use effective contraception or abstain from sexual intercourse during and after the treatment phase of the trial, in line with the trial site's guidelines.

Important: Always verify eligibility with the trial site directly before applying.